Skip to main content
SpringerLink
Log in

Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective

Type 2 diabetes mellitus (T2DM) is frequently associated with co-morbidities that exacerbate cardiovascular (CV) risk. CV disease is the leading cause of death in people with diabetes across the world and accounts for approximately half the deaths in the T2DM population. Hence, the objective of present study was to evaluate the cost-effectiveness of empagliflozin, in addition to standard of care (SoC), for the treatment of adult patients with T2DM and high CV risk in Greece.

Methods

A health economic model was used to project clinical and economic outcomes of patients receiving empagliflozin plus SoC compared with those receiving SoC alone over a lifetime horizon. CV and renal event rates were derived from patient level data from the EMPA-REG-OUTCOME® trial by fitting time-dependent parametric survival functions. 5000 individual patient profiles randomly sampled from the trial were simulated using a time-to-event approach. Model extrapolated outcomes included life years (LYs), quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). Following a Greek third-party payer perspective, only direct medical costs related to drug acquisition as well as fatal and non-fatal diabetes-related complications were considered (€2016). Cost units and utility data were extracted from the literature and publicly available official sources. Sensitivity analyses explored the impact of changes in input data.

Results

Over a patient’s lifetime, empagliflozin was predicted to result in longer mean survival (14.01 LY vs. 11.87 LY with SoC) and reduced rate of clinical events accumulating 7.75 QALYs versus 6.83 QALYs on SoC alone at additional costs of €4235. The generated ICER of empagliflozin was €4633 per QALY gained. One-way sensitivity analysis confirmed empagliflozin’s cost-effective profile. At the defined willingness-to-pay threshold of €34,000 per QALY gained, probabilistic sensitivity analysis showed that empagliflozin was estimated to have a 100% probability of being cost-effective relative to SoC.

Conclusions

Empagliflozin added to SoC was estimated to be a highly cost-effective treatment option for the treatment of T2DM in adults with increased CV disease risk in Greece.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. Global report on Diabetes. 2016; Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1. Accessed 11 Jan 2017.

  2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Liatis S, Dafoulas GE, Kani C, Politi A, Litsa P, Sfikakis PP, et al. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract. 2016;118:162–7.

    Article  PubMed  Google Scholar 

  4. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol. 2003;40(Suppl 2):S358–61.

    Article  PubMed  Google Scholar 

  5. Boldys A, Okopien B. Inhibitors of type 2 sodium glucose co-transporters–a new strategy for diabetes treatment. Pharmacol Rep. 2009;61(5):778–84.

    Article  CAS  PubMed  Google Scholar 

  6. Emerging Risk Factors, C., Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60.

    Article  Google Scholar 

  7. Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102.

    Article  PubMed  PubMed Central  Google Scholar 

  8. International Diabetes Federation. Diabetes, ATLAS Seventh Edition. 2015; Available from: http://www.diabetesatlas.org/. Accessed 14 Sept 2016.

  9. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes Vasc Dis Res. 2013;10(4):289–301.

    Article  Google Scholar 

  12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  13. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12(2):78–89.

    Article  CAS  Google Scholar 

  14. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  15. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kansal A, Zheng Y, Proskorovsky I, Krotneva S, Kandaswamy P, Ruffolo A. PDB37—modeling cardiovascular outcomes of treatment with empagliflozin in typer 2 diabetes based on hard outcomes data. Value Health. 2016;19(3):A203.

    Article  Google Scholar 

  17. Mettam SR, Bajaj H, Kansal AR, Kandaswamy P. PDB52—cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada. Value Health. 2016;19(7):A674.

    Article  Google Scholar 

  18. Daacke I, Kandaswamy P, Tebboth A, Kansal A, Reifsnider O. PDB46—cost-effectiveness of empagliflozin (jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on empa-reg outcome data. Value Health. 2016;19(7):A673.

    Article  Google Scholar 

  19. World Health Organization (WHO). Greece life tables. Available from: http://apps.who.int/gho/data/view.main.60640. Accessed 12 Sept 2016.

  20. Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, et al. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: an economic evaluation study. BMC Health Serv Res. 2015;15:307.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, et al. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hellenic J Cardiol. 2005;46(3):212–21.

    PubMed  Google Scholar 

  22. Gourzoulidis G, Kourlaba G, Kakisis J, Matsagkas M, Giannakoulas G, Gourgoulianis KI, et al. Cost-effectiveness analysis of rivaroxaban for treatment of deep vein thrombosis and pulmonary embolism in Greece. Clin Drug Investig. 2017;37(9):833–44.

    Article  CAS  PubMed  Google Scholar 

  23. Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health. 2016;19(8):1002–8.

    Article  PubMed  Google Scholar 

  24. Greek Ministry of Health. Drug price bulletin 2016. Available from: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn. Accessed 31 Dec 2016.

  25. Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014;14:419.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig. 2016;36(8):649–59.

    Article  PubMed  Google Scholar 

  27. Hellenic Statistical Authority (EL. STAT.). Inflation rates. Available from: http://www.statistics.gr/portal/page/portal/ESYE. Accessed 15 Dec 2016.

  28. Greek Ministry of Health. Diagnostic Related Groups. Available from: http://www.yyka.gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1. Accessed 20 Dec 2016.

  29. National Organisation for HealthcareServices Provision. Official web site of EOPYY. 2016; Available from: http://www.eopyy.gov.gr/Home/StartPage?a_HomePage=Index. Accessed 22 Dec 2016.

  30. WHO. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. 2013; Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 22 Jan 2017.

  31. International Monetary Fund. World Economic Outlook Database. 2017; Available from: http://www.imf.org/external/pubs/ft/weo/2017/01/weodata/index.aspx. Accessed 18 Jan 2017.

Download references

Author information

Authors and Affiliations

  1. Evroston LP, Athens, Greece

    George Gourzoulidis, Charalampos Tzanetakos & Georgia Kourlaba

  2. Diabetes Centre, Department of Internal Medicine, Konstantopouleio Hospital, Athens, Greece

    Ioannis Ioannidis

  3. Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece

    Apostolos Tsapas

  4. Βoehringer Ingelheim Ηellas, Athens, Greece

    Giannis Papageorgiou

  5. Department of Health Services Organization and Management, National School of Public Health, Athens, Greece

    Nikos Maniadakis

Authors
  1. George Gourzoulidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charalampos Tzanetakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ioannis Ioannidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Apostolos Tsapas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georgia Kourlaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giannis Papageorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nikos Maniadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George Gourzoulidis.

Ethics declarations

Funding

This study was funded by Βoehringer Ingelheim Hellas. However, the study sponsor had no interference in the study design, data collection, data analysis, or writing of the manuscript.

Conflict of interest and financial disclosure

II received honoraria for lectures from Boehringer Ingelheim. NM received speaker honoraria and consulting fees from Boehringer Ingelheim. AT received consulting fees and honoraria for lectures from Boehringer Ingelheim.GP is a Boehringer Ingelheim employee. None of the other authors has any personal or financial conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 26 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gourzoulidis, G., Tzanetakos, C., Ioannidis, I. et al. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. Clin Drug Investig 38, 417–426 (2018). https://doi.org/10.1007/s40261-018-0620-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0620-x

Search

Navigation